DeVries JH, et al. - This study gathered data from two double-blind, randomized, treat-to-target, two-period (32 weeks each) crossover trials to examine the relationship between day-to-day fasting self-monitored blood glucose (SMBG) variability and risk of hypoglycemia in type 1 (T1D) and type 2 diabetes (T2D), as well as the day-to-day fasting SMBG variability seen with insulin degludec (degludec) vs insulin glargine 100 units/mL (glargine U100). Findings suggested an association of higher day-to-day fasting SMBG variability with an increased risk of overall symptomatic, nocturnal symptomatic and severe hypoglycemia. It was noted that degludec was related to 4% lower day-to-day fasting SMBG variability vs glargine U100 in T1D and 10% lower day-to-day fasting SMBG variability in T2D.